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Abstract : Triple-negative breast cancer （TNBC） accounts for 10-15％ of all breast 
cancer cases and shows a poor prognosis with 30％ distant metastasis.  With few 
specific target molecules and ineffective hormonal and anti-HER2 treatment, an 
alternative therapeutic method for TNBC is urgently required.  Recently, a non-
taxane inhibitor of microtubule dynamics called eribulin was developed for breast 
cancer therapy.  Eribulin induces irreversible mitotic mass formation in cancer cells 
during the G2-M phase, initiating apoptosis ; however, the mechanism underlying 
this eribulin activity remains unclear.  We reported previously that exposing non-
basal-like （NBL） TNBC cells to eribulin increases miR-195 expression, which in 
turn decreases the expression of targeted Wnt3a.  The present study sought to 
further clarify the mechanism of this antitumor effect by exploring how eribulin 
affects Wnt/β-catenin signaling based on miRNA expression changes in TNBC.  In 
an NBL type of human breast cancer cell line （MDA-MB-231 cells）, we compared 
the expression levels of Wnt/β-catenin signaling pathway proteins in cells exposed 
to an miR-195 mimic （cells transfected with miR-195 and in which Wnt3a expres-
sion was suppressed） and in cells exposed to eribulin.  Expression levels of Wnt3a, 
β-catenin, and GSK-3β were measured by ELISA and observed by uorescence 
immunostaining.  Wnt3a and β-catenin expression was significantly lower and 
GSK-3β expression was signicantly higher in the cells exposed to eribulin and 
transfected with miR-195 mimic than in the untreated controls, suggesting that erib-
ulin inactivates the Wnt/β-catenin signaling pathway.  Therefore, a novel antitumor 
mechanism of eribulin was determined, whereby eribulin induces high expression of 
miR-195 to inactivate the Wnt/β-catenin signaling pathway in NBL-type TNBC.
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Introduction
　Breast cancer is the most common cancer in women and is classified into subtypes based 
on its gene expression.  Triple-negative breast cancer （TNBC） is negative for estrogen receptor 
（ER）, progesterone receptor （PgR）, and human epidermal growth factor receptor 2 （HER2） 
expression.  TNBC accounts for 10-15％ of all breast cancer cases and shows a poor prognosis 
with a 30％ chance of distant metastasis; however, no specic therapeutic target molecules have 
been reported for TNBC, and hormone or anti-HER2 treatments are not effective.  Thus, a new 
therapeutic strategy involving specic targets is urgently required 1-3）.  TNBC is a disease with a 
poor prognosis 1-3） and no denite therapeutic target, other than BRCA1/2, has been identied, 
despite many trials.  In 2011, TNBC was subdivided into six types, namely basal cell-like type 1 
（BL-1）, basal cell-like type 2 （BL-2）, immunomodulatory type （IM）, mesenchyme-like type （M）, 
mesenchymal stem cell-like type （MSL）, and luminal androgen receptor type （LAR）2, 4）.  Estab-
lishing a target for each subtype is also needed for the development of effective therapeutic 
agents.
　One candidate therapeutic agent proposed for TNBC is eribulin mesilate, a non-taxane 
microtubule dynamics inhibitor that induces irreversible mitotic mass formation at the G2-M 
phase and induces apoptosis in cancer cells 5-9）.  A purported antitumor mechanism for eribulin 
involves the suppression of microtubule elongation due to their polymerization without affecting 
shortening of microtubules, aggregation of microtubule monomers, or microtubules themselves 5-10）. 
This function of eribulin could intersect with the wingless-type MMTV integration site family 
（Wnt）/β-catenin signaling pathway, a pivotal regulator of cell proliferation and differentiation, 
as well as embryogenesis and tumorigenesis 11, 12）.  Activation of Wnt/β-catenin signaling has 
been reported in several cancers, such as colorectal cancer, ovarian cancer, and breast cancer 13）. 
In particular, the activation of this pathway is frequently observed in TNBC and is reportedly 
related to this cancer’s poor prognosis 14, 15）.  
　Another potential target of eribulin is cellular microRNA （miRNA）.  These regulatory non-
coding RNAs （19-25 nucleotides in length） bind complementarily to a specic target nucleotide 
of the 3’-untranslated region （UTR） of mRNA and can inhibit the expression of both mRNA 
and protein 16-20）, although the potential antitumor mechanisms of miRNAs remain ill-defined. 
Our previous study 21） suggested an association between miRNA and eribulin in MDA-MB-231 
cells, but there is no other published data regarding the miRNA-mediated antitumor mechanism 
of eribulin.  We speculated that the miRNA that regulates Wnt3a, an upstream protein of the 
Wnt/β-catenin signaling pathway, is involved in the antitumor mechanism of eribulin.
　Therefore, we aimed herein to analyze miRNA expression as a potential mechanism of eribu-
lin’s activity in TNBC cells and to clarify the inuence of eribulin on the Wnt/β-catenin signal-
ing pathway.
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Materials and methods  
Cell lines and culture conditions
　The human non-basal-like （NBL） type of the TNBC cell line MDA-MB-231 （mesenchymal 
cell-like type） was derived from the Japanese Cancer Resources Bank （Osaka, Japan）.  MDA-
MB-231 cells were cultured in Dulbecco’s modied Eagle’s medium （DMEM） Ham/F12 （Sigma-
Aldrich, Oberhaching, Germany） supplemented with 10％ fetal bovine serum （Gibco Life Tech-
nologies, Carlsbad, CA, USA）, 100 units/ml penicillin/100 mg/ml streptomycin （GIBCO penicillin-
streptomycin liquid ; Invitrogen, CA, USA）.  We also added 1 mM pyruvic acid （Sigma-Aldrich） 
to the DMEM.  The cells were incubated at 37°C and with 5％ carbon dioxide.
Eribulin Compound 
　MDA-MB-231 cells were seeded in 6-well plates or 10 cm-diameter plates and treated with a 
nal concentration of 1 nM eribulin mesilate （C40H59NO11・CH4O3S ; MW, 826.00） （HalavenⓇ, 
Eisai Co., Ltd, Shinjuku-ku, Tokyo, Japan）, as set in our previous study 21）.
Transfection
　We generated miRNA mimics of miR-195-5p complementary to the 5’-UTR using the 
miRCURY LNATM microRNA Mimic （Exiqon Inc., Vedbaek, Denmark）, with nucleic acid 
sequences as follows : （http://www.exiqon.com/mirna-inhibitors）; 
has-miR-195-5p : 5’-rUrArGrCrArGrCrArCrArGrArArArUrArUrUrGrGrC-3’.
　The MDA-MB-231 cells were then transfected with each miRNA mimic by lipofection.  For 
transient transfections, the cells were seeded at low density （1×106 cells/ml） in 6-well dishes and 
transfected with 100 pmol of each miRNA mimic using LipofectamineⓇ 2,000 transfection reagent 
（Thermo Fisher Scientic K.K., Waltham, MA, USA）.  At 4 h after transfection, the cells were 
washed and incubated in complete DMEM for 48 h.
miRNA analysis
　MDA-MB-231 cells （1×10 6 cells/10 ml） were cultured in 10-cm dishes and treated with 1 nM 
eribulin for 24 h, before the miRNA extractions using miRNeasy Mini kit （Qiagen, Tokyo, 
Japan）.  Next, cDNAs were synthesized from 500 ng miRNAs by using miScript Ⅱ RT kit （Qia-
gen, Tokyo, Japan） and miR-195 expression was measured by PCR array （miScript miRNA PCR 
array for human breast cancer, MIHS-109ZA ; Qiagen）.  PCR was performed using the miRNA 
MiScript SYBR Green human breast cancer miRNA PCR kit （Qiagen） and ABI PRISM 7000 
Sequence System （Applied Biosystems Inc., Foster City, CA, USA） under the following condi-
tions : initial denaturation at 95°C for 10 min, followed by 40 cycles of denaturation at 94°C for 
15 sec, annealing at 60°C for 30 sec, and extension at 72°C for 30 sec.  Data were analyzed 
using the ΔΔCt method （original expression level ＝ 2－ΔΔCt） and expressed as a ratio （ΔΔCt） 
of Ct level in eribulin-treated cells to that in untreated MDA-MB-231 cells.
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ELISA for WNT3a, β-catenin, and GSK-3β
　The expressions of wingless-type mouse mammary tumor virus （MMTV） integration site, mem-
ber 3A （Wnt3a） and β-catenin were detected using an enzyme-linked immunosorbent assay kit 
（SEP155Hu ; Uscn Life Science, Wuhan, Hubei, China） and catenin Beta 1 （CTNNb1） enzyme-
linked immunosorbent assay kit （E91021Hu ; Uscn Life Science）, respectively.  The expression 
of GSK-3β was detected using a GSK-3beta sandwich ELISA kit （7265CK ; Cell Signaling 
Technology, Danvers, MA, USA） and P-GSK-3beta（S9） sandwich ELISA kit （7311CK ; Cell 
Signaling Technology,）.  All detection assays were analyzed using a uorospectrophotometer （λ
＝ 450 nm ; Spectra Max i3 ; Molecular Devices Co., Sunnyvale, CA, USA）.  
Fluorescent immunohistochemistry
　The sections were treated with 0.3％ H2O2 for 5 min to remove endogenous peroxidases, 
before incubation in a non-specic blocking reagent （X0909, DAKO, Glostrup, DK） for 5 min. 
The section were then incubated with primary antibodies, anti-WNT3A rabbit antibody （1：100, 
HPA050514 ; Atlas Antibodies, Stockholm, Sweden） or anti P-GSK-3 beta （S9） rabbit mAb （1：
200, 9323S ; Cell Signaling Technology）, for 1 h at room temperature, followed by incubation 
with TRIC-conjugated anti-rabbit IgG secondary antibodies （A21428, Life Technologies） in a 
humid chamber at 37°C for 30 min.  Sequentially, sections were incubated with puried mouse 
anti-beta-catenin at 37°C for 1 h followed by FITC-conjugated anti-mouse IgG （A11001, Life 
Technologies） for 30 min.  Sections were nally counterstained to visualize nuclei with bisbenz-
imide H33342 （Hoechst 33342）, and imaged using a Delta Vision microscope （AIRIX Corp., 
Tokyo, Japan）.
Statistical analysis
　Signicant differences between the groups were determined by two-way analysis of variance 
（ANOVA） with Bonferroni’s post-hoc test.  Significance of miRNA analysis was assessed by 
ANOVA using the miScript miRNA PCR Array Data Analysis software （Qiagen）, with the 
signicance level set at P＜ 0.05.
Results 
Analysis of miRNA expression 
　We examined the expression of miRNAs targeting Wnt3a in MDA-MB-231 cells after exposure 
to eribulin.  ΔΔCT values for miR-15a, miR-16, miR-27a, and miR-195 were 38.5, 129.79, 138.78, 
and 102.06, respectively, indicating higher expression of all these miRNAs after eribulin exposure 
compared to levels in the control cells （Fig. 1）.
Analysis of ELISA
　The miRNA, miR-195, was shown to target Wnt3a in breast cancer in our previous study 21）. 
In this study, we therefore compared and examined the expression levels of proteins in the 
Wnt/β-catenin signaling pathway, namely Wnt3a, GSK-3β, and β-catenin, in MDA-MB-231 
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cells after transfection with a miR-195 mimic （miR-195 mimic group） and exposure to eribulin 
（eribulin group）.  Wnt3a expression was signicantly lower in the miR-195 mimic group （0.298 ±
0.01 ng/ml） and eribulin group （0.306 ± 0.067 ng/ml） than in the untreated control group （0.563 
± 0.011 ng/ml） （Fig. 2）.  In contrast, phosphorylated GSK-3β expression was signicantly higher 
in the miR-195 mimic group （1.11 ± 0.05％） and eribulin group （0.774 ± 0.02％） than in the 
untreated control group （0.212 ± 0.015％） （Fig. 3）, whereas β-catenin expression was signicantly 
lower in the miR-195 mimic group （0.046 ± 0.004 ng/ml） and eribulin group （0.025 ± 0.002 ng/ml） 
than in the untreated controls （0.069 ± 0.005 ng/ml） （Fig. 4）.
Fig. 1.  Cells after exposure to eribulin
The expressions of miRNAs targeting Wnt3a were 
analyzed in the MDA-MB-231 cells after eribulin 
exposure. The miR-15a, miR-16, miR-27a, and miR-195 
expression levels in MDA-MB-231 cells increased after 
exposure to eribulin by 38.05, 129.79, 138.78, and 102.06 
times, respectively.
Fig. 2.  Comparison of Wnt3a expression levels
Expression levels of Wnt3a were significantly lower in 
eribulin-exposed and miR-195 mimic-transfected MDA-
MB-231 cells than in untreated controls. Data are 
expressed as mean± SD （n＝4）. ＊P＜0.05 compared with 
untreated controls ; Bonferroni’s multiple comparison test.
Fig. 3.  Comparison of GSK-3β phosphorylation
GSK-3β phosphorylation was significantly higher in 
miR-195 mimic-transfected and eribulin-exposed cells than 
in untreated controls. Data are expressed as mean ± SD 
（n＝4）. ＊P＜0.05 compared with untreated controls ; 
Bonferroni’s multiple comparison test.
Fig. 4.  Comparison of β-catenin expression levels
Expression levels of β-catenin were significantly higher 
in MDA-MB-231 cells treated with miR-195 mimic and 
eribulin than in untreated controls. Data are expressed as 
mean ± SD （n＝4）. ＊P＜0.05 compared with untreated 
controls ; Bonferroni’s multiple comparison test.
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Immunohistochemical staining
　We next examined the expression patterns of Wnt/β-catenin signaling proteins in the MDA-
MB-231 cells by immunouorescence.  The untreated control group showed higher cytoplasmic 
expression of Wnt3a than the miR-195 mimic and eribulin groups （Fig. 5）, and higher expression 
of β-catenin localized in the nucleus and cytoplasm （arrow）.  In contrast, the miR-195 mimic 
group and the eribulin group showed higher expressions of pGSK-3β in the cytoplasm than the 
untreated control group （Fig. 6）.
Discussion
　First, we identied miRNAs that were involved in the Wnt/β-catenin signaling pathway.  In 
eribulin-treated MDA-MB-231 cells, miR-15a, miR-16, miR-27a, and miR-195 were more highly 
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Fig. 5.  Immunohistochemical staining of Wnt3a
（A） The nuclei of control cells were visualized with a blue DAPI stain. （B） The untreated MDA-MB-231 cell 
controls were positive for Wnt3a （red）. （C） Immunofluorescence images showing the localization of Wnt3a 
（red） and DAPI-stained （blue） nuclei in control cells. （D） DAPI-stained nuclei of MDA-MB-231 cells after 
transfection with the miR-195 mimic. （E） Wnt3a was weakly expressed in MDA-MB-231 cells after transfection 
of the miR-195 mimic. （F） The low expression of Wnt3a in MDA-MB-231 cells after the transfection of miR-
195 mimic. （G） DAPI-stained nuclei of MDA-MB-231 cells after the exposure to eribulin. （H） Wnt3a was 
weakly expressed. （I） Immunofluorescence images of Wnt3a （red） and DAPI-stained （blue） nuclei of MDA-
MB-231 cells after the exposure to eribulin.  Scale bar : 20 µm.
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expressed than in the untreated control cells, and these miRNAs have been reported to target 
Wnt3a 21-28）．Moreover, miR-195 targets encoding mRNAs, such as Wnt3a, cyclinD1, CDK4/6, 
cyclinE1, WEE1, E2F3, and BCL2, and binds complementarily to the base sequence of their 
UTRs to inhibit mRNA translation and protein expression 26, 29-35）.  In addition, miR-195 shows 
potential tumor suppressive action in bladder cancer 30）, and inhibits cell proliferation in the liver 
by the induction of INF 31）.  In breast cancer, strong expression of miR-195 has been inversely 
correlated with tumor size, lymph node metastasis, and vascular invasion 36）, whereas low expres-
sion of miR-195 has been linked to a poor prognosis 37）.  
　Based on the reports above, we transfected an miR-195 mimic into MDA-MB-231 cells to 
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Fig. 6.  Immunohistochemical staining of β-catenin and GSK-3β 
（A） DAPI-stained （blue） nuclei of control cells. （B） GSK-3β immunostaining in untreated MDA-MB-231 
cells showed low expression levels. （C） Immunohistochemical staining of anti-β-catenin in untreated MDA-
MB-231 cells （arrow）. （D） Double immunofluorescence images of β-catenin （green） and GSK-3β （red） in 
control cells, with DAPI-stained nuclei （blue）. （E） DAPI-stained nuclei of MDA-MB-231 cells after eribulin 
exposure and miR-195 mimic transfection, with （F） GSK-3β expression after transfection of miR-195 mimic. 
（G） Immunopositive staining of β-catenin was localized in the cytoplasm and membrane of MDA-MB-231 cells 
after transfection of miR-195 mimic. （H） The number of GSK-3β-positive MDA-MB-231 cells increased after 
transfection of miR-195 mimic compared with that of control cells. （I） DAPI-stained nuclei of MDA-MB-231 
cells after eribulin exposure, with （J） GSK-3β-positive signals localized in the cell cytoplasm. （K） β-catenin-
positive signals were localized in the cytoplasm and membrane of MDA-MB-231 cells after eribulin exposure. 
（L） The double immunofluorescence imaging of β-catenin （green） and GSK-3β （red）, as well as DAPI-
stained （blue） nuclei of MDA-MB-231 cells after eribulin exposure.  Scale bar : 20 µm.
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induce high expression of miR-195 and to analyze the subsequent activation of Wnt/β-catenin 
signaling.  The miR-195 mimic-transfected cells showed significantly lower Wnt3a expression 
than control cells and miR-195 was bound complementarily to Wnt3a-encoding RNA （Wnt3A）, 
inhibiting Wnt3a translation and protein expression.  Furthermore, since Wnt3a expression was 
also significantly reduced after eribulin exposure, we proposed that expression of miR-195 
was enhanced and expression of Wnt3a was suppressed by exposure to eribulin.  In addition, 
immunouorescence examination revealed that the cytoplasm of untreated control cells showed 
higher expression of Wnt3a than cells in the miR-195 mimic and eribulin groups.  These results 
indicated that miR-195 mimic transfection and the exposure to eribulin attenuated the expression 
of Wnt3a in MDA-MB-231 cells.
　Next, we examined the expression levels of GSK-3β and β-catenin in the treated cells. 
GSK-3β phosphorylation was signicantly increased in the miR-195 mimic and eribulin groups 
compared to the untreated control group, while β-catenin expression was signicantly decreased. 
These results revealed that miR-195 mimic transfection and the eribulin exposure caused the 
phosphorylation of β-catenin GSK-3β and the subsequent ubiquitination and degradation of β- 
catenin.  Furthermore, immunouorescence staining revealed higher and more concentrated β- 
catenin expression in the nucleus and cytoplasm of the untreated control group than in the 
cytoplasm of the miR-195 mimic-transfected and eribulin-exposed group.  In contrast, pGSK-3β 
expressions in the cytoplasm of the miR-195 mimic group and eribulin group were higher than 
in the untreated control group, attributing the attenuation of β-catenin expression to the high 
expression of GSK-3β.  
　In the Wnt/β-catenin signaling pathway of the untreated control cells, GSK-3β is not phos-
phorylated by binding to the receptor on the cell membrane, whereas β-catenin is stabilized 
and accumulated in the cytoplasm before being transferred into the nucleus.  In the nucleus, β- 
catenin binds to the transcription factor T cell factor/lymphocyte enhancing factor （Tcf/Lef） 
and promotes the expression of genes that regulate cell cycle progression, such as cyclin D1 
and c-myc11, 12, 38）.  On the contrary, in the miR-195 mimic group and eribulin group, GSK-3β 
expression decreased the amount of cytoplasmic β-catenin, possibly via the binding of β- 
catenin to axin along with adenomatous polyposis coli （APC） and GSK-3β, forming an Axin 
complex, which is then phosphorylated by casein kinase 1 （CK1） and GSK-3β, ubiquitinated, 
and degraded by the proteasome39-41）． 
　Activation of the Wnt/β-catenin signaling pathway also promotes TNBC metastasis 15） as well 
as cell proliferation and differentiation 42）; however, it is possible that eribulin inactivates the 
Wnt/β-catenin signaling pathway directly and induces apoptosis in cancer cells by suppressing 
Wnt3a expression through high expression of miR-19543, 44） （Fig. 7）．
　In 2014, miR-195 was implicated as a tumor suppressor directly targeting Wnt3a 26, 44）．This 
study also revealed that exposure to eribulin enhanced the expression of miR-195, which sup-
pressed Wnt3a expression.  In the present study, miR-195 mimic transfection and exposure to 
eribulin group also suppressed cellular β-catenin expression.  Taken together, these ndings sug-
gest that eribulin exposure could suppress the expression of Wnt3a by enhancing the expression 
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of miR-195 and directly inactivating the Wnt/β-catenin signaling pathway, in a possible mecha-
nism underlying its antitumor effect.
　The mechanism by which eribulin inactivated the Wnt/β-catenin signaling pathway in TNBC 
cells could not be sufciently examined in this study, because Wnt3a expression was suppressed 
by high expression of miR-195.  However, this newly reported mechanism of eribulin action is 
potentially useful for similar mechanistic investigation of other anticancer agents in various types 
of cancer cells and the development of new drugs.
Conclusion
　The present study revealed a potential antitumor mechanism by which eribulin increased miR-
195 expression and suppressed Wnt3a expression in a cell model of non-basal cell-type TNBC, 
thereby inactivating the Wnt/β-catenin signaling pathway and inhibiting cell proliferation．
Fig. 7.  Wnt/β-catenin signaling pathway in the absence or presence of eribulin in MDA-MB-231 cells 
In the absence of eribulin, Wnt3a binds to the receptor on the cell membrane, preventing GSK-3β 
phosphorylation as well as β-catenin dissociation and stabilization into the nucleus. Consequently, the 
proteins involved in the cell cycle progression are transcripted, the cell cycle progresses, and then the cancer 
cells proliferate. In the presence of eribulin, miR-195 is upregulated and the expression of complementary 
Wnt3a is decreased. β-catenin binds to Axin together with APC and GSK-3β, forming an Axin 
complex, which is phosphorylated by CK1 and GSK-3β, ubiquitinated, and degraded by the proteasome. 
Consequently, protein transcription does not proceed, the cell cycle is arrested, and cell death is imminent.
Keinosuke OKAZAKI, et al368
Conict of interest disclosure
　The authors have no conflict of interest to disclose.
References
1） Brewster AM, Chavez-MacGregor M, Brown P. Epidemiology, biology, and treatment of triple-negative breast 
cancer in women of African ancestry. Lancet Oncol. 2014;15:e625-e634.
2） Lehmann BD, Bauer JA, Chen X, et al. Identication of human triple-negative breast cancer subtypes and pre-
clinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750-2767.
3） Yao H, He G, Yan S, et al. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget. 
2017;8:1913-1924.
4） Lehmann BD, Pietenpol JA. Clinical implications of molecular heterogeneity in triple negative breast cancer. 
Breast. 2015;24 Suppl 2:S36-S40.
5） Towle MJ, Salvato KA, Budrow J, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone 
analogues of halichondrin B. Cancer Res. 2001;61:1013-1021.
6） Kuznetsov G, Towle MJ, Cheng H, et al. Induction of morphological and biochemical apoptosis following pro-
longed mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 2004;64:5760-5766.
7） Munoz-Couselo E, Perez-Garcia J, Cortes J. Eribulin mesylate as a microtubule inhibitor for treatment of patients 
with metastatic breast cancer. Onco Targets Ther. 2011;4:185-192.
8） Towle MJ, Salvato KA, Wels BF, et al. Eribulin induces irreversible mitotic blockade: implications of cell-based 
pharmacodynamics for in vivo efcacy under intermittent dosing conditions. Cancer Res. 2011;71:496-505.
9） Pean E, Klaar S, Berglund EG, et al. The European medicines agency review of eribulin for the treatment of 
patients with locally advanced or metastatic breast cancer: summary of the scientic assessment of the committee 
for medicinal products for human use. Clin Cancer Res. 2012;18:4491-4497.
10）Yoshida T, Ozawa Y, Kimura T, et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells 
by reversing phenotype from epithelial-mesenchymal transition （EMT） to mesenchymal-epithelial transition （MET） 
states. Br J Cancer. 2014;110:1497-1505.
11）Kikuchi A. Roles of Axin in the Wnt signalling pathway. Cell Signal. 1999;11:777-788.
12）Kikuchi A, Yamamoto H, Kishida S. Multiplicity of the interactions of Wnt proteins and their receptors. Cell 
Signal. 2007;19:659-671.
13）Najdi R, Holcombe RF, Waterman ML. Wnt signaling and colon carcinogenesis: beyond APC. J Carcinog. 
2011;10:5.
14）Yang L, Perez AA, Fujie S, et al. Wnt modulates MCL1 to control cell survival in triple negative breast cancer. 
BMC Cancer. 2014;14:124.
15）Dey N, Barwick BG, Moreno CS, et al. Wnt signaling in triple negative breast cancer is associated with metas-
tasis. BMC Cancer. 2013;13:537. （accessed 2018 Feb 14） Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC4226307/pdf/1471-2407-13-537.pdf
16）Bertoli G, Cava C, Castiglioni I. MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and 
therapeutic tools for breast cancer. Theranostics. 2015;5:1122-1143.
17）D’Ippolito E, Iorio MV. MicroRNAs and triple negative breast cancer. Int J Mol Sci. 2013;14:22202-22220.
18）Hu C, Shen SQ, Cui ZH, et al. Effect of microRNA-1 on hepatocellular carcinoma tumor endothelial cells. World 
J Gastroenterol. 2015;21:5884-5892.
19）Ouyang M, Li Y, Ye S, et al. MicroRNA proling implies new markers of chemoresistance of triple-negative breast 
cancer. PLoS One. 2014;9:e96228.
20）Yang F, Zhang W, Shen Y, et al. Identification of dysregulated microRNAs in triple-negative breast cancer 
369Eribulin Inactivates Wnt/β-catenin Signals in TNBC
（review）. Int J Oncol. 2015;46:927-932.
21）Furuya K, Sasaki A, Tsunoda Y, et al. Eribulin upregulates miR-195 expression and downregulates Wnt3a expres-
sion in non-basal-like type of triple-negative breast cancer cell MDA-MB-231. Hum Cell. 2016;29:76-82.
22）Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. 
Cell Death Differ. 2010;17:215-220.
23）Bonci D, Coppola V, Musumeci M, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting mul-
tiple oncogenic activities. Nat Med. 2008;14:1271-1277.
24）Chang M, Lin H, Fu H, et al. MicroRNA-195-5p regulates osteogenic differentiation of periodontal ligament cells 
under mechanical loading. J Cell Physiol. 2017;232:3762-3774.
25）Wang ZM, Wan XH, Sang GY, et al. miR-15a-5p suppresses endometrial cancer cell growth via Wnt/beta-catenin 
signaling pathway by inhibiting WNT3A. Eur Rev Med Pharmacol Sci. 2017;21:4810-4818.
26）Yang Y, Li M, Chang S, et al. MicroRNA-195 acts as a tumor suppressor by directly targeting Wnt3a in HepG2 
hepatocellular carcinoma cells. Mol Med Rep. 2014;10:2643-2648.
27）Zhang XJ, Ye H, Zeng CW, et al. Dysregulation of miR-15a and miR-214 in human pancreatic cancer. J Hematol 
Oncol. 2010;3:46.
28）Zhao Y, Wang P, Meng J, et al. MicroRNA-27a-3p inhibits melanogenesis in mouse skin melanocytes by targeting 
Wnt3a. Int J Mol Sci. 2015;16:10921-10933.
29）Etemadmoghadam D, Au-Yeung G, Wall M, et al. Resistance to CDK2 inhibitors is associated with selection of 
polyploid cells in CCNE1-amplied ovarian cancer. Clin Cancer Res. 2013;19:5960-5971.
30）Lin Y, Wu J, Chen H, et al. Cyclin-dependent kinase 4 is a novel target in micoRNA-195-mediated cell cycle arrest 
in bladder cancer cells. FEBS Lett. 2012;586:442-447.
31）Sekiya Y, Ogawa T, Iizuka M, et al. Down-regulation of cyclin E1 expression by microRNA-195 accounts for 
interferon-beta-induced inhibition of hepatic stellate cell proliferation. J Cell Physiol. 2011;226:2535-2542.
32）Sun Y, Luo D, Liao DJ. CyclinD1 protein plays different roles in modulating chemoresponses in MCF7 and MDA-
MB231 cells. J Carcinog. 2012;11:12.
33）Vimala K, Sundarraj S, Sujitha MV, et al. Curtailing overexpression of E2F3 in breast cancer using siRNA （E2F3）- 
based gene silencing. Arch Med Res. 2012;43:415-422.
34）Wu CL, Kirley SD, Xiao H, et al. Cables enhances cdk2 tyrosine 15 phosphorylation by Wee1, inhibits cell growth, 
and is lost in many human colon and squamous cancers. Cancer Res. 2001;61:7325-7332.
35）Xu Z, Li C, Qu H, et al. MicroRNA-195 inhibits the proliferation and invasion of pancreatic cancer cells by tar-
geting the fatty acid synthase/Wnt signaling pathway. Tumour Biol. 2017;39:1010428317711324. （accessed 2018 Mar 
14） Available from: http://journals.sagepub.com/doi/pdf/10.1177/1010428317711324
36）Li D, Zhao Y, Liu C, et al. Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. 
Clin Cancer Res. 2011;17:1722-1730.
37） Song CG, Wu XY, Wang C, et al. ［Correlation of miR-195 with invasiveness and prognosis of breast cancer］. 
Zhonghua Wai Ke Za Zhi. 2012;50:353-356.
38）Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004; 
20:781-810.
39）Ikeda S, Kishida S, Yamamoto H, et al. Axin, a negative regulator of the Wnt signaling pathway, forms a complex 
with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J. 
1998;17:1371-1384.
40）Kitagawa M, Hatakeyama S, Shirane M, et al. An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis 
of beta-catenin. EMBO J. 1999;18:2401-2410.
41）Liu C, Li Y, Semenov M, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. 
Cell. 2002;108:837-847.
Keinosuke OKAZAKI, et al370
42）Maubant S, Tesson B, Maire V, et al. Transcriptome analysis of Wnt3a-treated triple-negative breast cancer cells. 
PLoS One. 2015;10:e0122333.
43）Green JL, La J, Yum KW, et al. Paracrine Wnt signaling both promotes and inhibits human breast tumor growth. 
Proc Natl Acad Sci USA. 2013;110:6991-6996.
44）Wang SH, Li N, Wei Y, et al. beta-catenin deacetylation is essential for WNT-induced proliferation of breast cancer 
cells. Mol Med Rep. 2014;9:973-978.
［Received May 2, 2018 : Accepted June 6, 2018］ 
